SOME CLINICAL ASPECTS OF LIPITENSION
DOI:
https://doi.org/10.11603/1811-2471.2018.v0.i2.8634Keywords:
arterial hypertension, cholesterol, lipoproteins.Abstract
The purpose of the study is to evaluate the effectiveness of modern antihypertensive therapy in combination with statin therapy and ursodeoxycholic acid (UDCA) in patients with lipentia (arterial hypertension (hypertension) and hypercholesterolemia).
Material and Methods. 36 patients with hypertonic disease (HD) of stage II, grade 2-3 and hypercholesterolemia were examined, which were performed a comprehensive clinical study, monitoring blood pressure (BP), and lipid metabolism on the basis of therapy by Difors, Atorvacor and Ursochol.
Results. The results of monitoring blood pressure indicate the beneficial effect of this treatment on the daily blood pressure profile: after 2 months of treatment was recorded a significant reduction in average daily systolic and diastolic blood pressure. Under the influence of atorvastatin and ursochol, lipid metabolism rates improved, which was manifested by a significant decrease in the level of total cholesterol and low density lipoprotein cholesterol, a tendency to increase the content of high density lipoprotein.
Conclusions. In this article the combined use of antihypertensive therapy, statin therapy and ursochol in patients with lipentia, especially in clinical cases in which it is necessary to limit the dosage of statins in terms of improving the prognosis of patients with HD due to the synergism of antihypertensive and lipid-lowering potential and pleiotropic effects of these drugs, the effect which is aimed at slowing the progression of HD and atherosclerosis, was justified.
References
Mancia, G., Fagard, R., & Narkiewicz, K. (2013). Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J. Hypertension, 31, 1925-1938.
Yusuf, S., Phil, D., & Bosch, J. (2016). Cholesterol lowering in intermediate-risk persons without cardiovascular disease. New Engl. J. Med., 374, 2021-2031.
Yusuf, S., Sleight, P., & Anderson, C. (2008). Telmisartan, Ramipril, or both for patients of high risk of vascular events. New Engl. J. Med., 358, 1547-1559.
